What EarlyFit does

EarlyFit, now operating as Voy India following its June 2026 acquisition by London-based Voy, runs a doctor-led digital weight loss platform that delivers GLP-1 obesity care to India's 150 million obese population. The core offering combines an online eligibility assessment, endocrinologist-led consultations, at-home cold-chain delivery of generic semaglutide medication, lifestyle coaching, at-home lab testing, and a companion mobile app with smart scale integration tracking 14+ body vitals. The business model is subscription-recurring, with bundled pricing that covers medication, ongoing medical oversight, and lifestyle support, backed by a money-back guarantee requiring 10% body weight loss within six months.

Founded by Parth and Saloni as one of India's first doctor-led GLP-1 ecosystems, EarlyFit was fully acquired by Voy on 2026-06-08 to bring Voy's global clinical expertise and integrated care model into the Indian market, timed to capitalize on the March 2026 expiration of Ozempic's patent in India. The medical team comprises senior endocrinologists trained at India's premier institutions — Apollo Delhi, AIIMS Delhi, AIIMS Jodhpur, Army Hospital, and Safdarjung — and global medical leadership under Dr. Earim Chaudry (Chief Medical Officer, Voy) and Dr. Saptarshi Bhattacharya (Chief Medical Advisor, Voy India). A clinical study of 57,975 Voy participants conducted with Imperial College London reports 53% more weight loss for Voy program users compared with medication-only treatment.

Go-to-market is product-led and digital: customers self-check eligibility online, download the mobile app (iOS/Android), enroll via subscription without sales intervention, and receive medication via door-to-door cold chain delivery. Distribution layers in doctor-consultation marketing and earned media across Indian publications (Indian Express, Times of India, Hindustan Times, News18, BioSpectrum India), with Trustpilot (4.7/5, 18k reviews) and App Store (4.8/5, 4.2k reviews) ratings functioning as trust signals. Strategic academic partnerships span Imperial College London, University of Oxford, University of Birmingham, Ulster University, University of Hertfordshire, and the Federal University of Minas Gerais, supporting clinical validation across Voy's four-country footprint (UK, Germany, Brazil, India).

Name

EarlyFit

Legal name

EarlyFit

Website

https://early.fit

Company type

Private

Founded year

2025

Operating status

Acquired

Headcount range

1–10 employees

Short description

EarlyFit, now Voy India following Voy's June 2026 acquisition, runs a doctor-led digital GLP-1 weight loss platform serving India's 150 million obese population with endocrinologist consultations, cold-chain generic semaglutide delivery, and smart scale-integrated mobile app tracking.

Ownership category

akta.pro rank

Product category

Digital Health / Telehealth Weight Management

NAICS

Diet and Weight Reducing Centers (812191)

SIC

Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Home Health Care Services (8082)

akta.pro primary industry

Weight Loss Coaching (Non-Clinical) (HSADAFAB)

Keywords

• Online weight loss program
• GLP-1 medication treatment
• Telehealth weight management
• Digital obesity care
• Doctor-supervised weight loss

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations, Supply Chain, Others

Revenue model

1. GLP-1 Medication Subscription: Recurring subscription for GLP-1 medication (generic semaglutide) delivered to patients. Program includes doctor consultations, at-home medication delivery, side effect support, and lifestyle coaching. Following Ozempic's patent expiration in India in March 2026, affordable generic options are offered.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

Core offering

EarlyFit is an online, doctor-supervised weight loss platform based in India that combines GLP-1 (semaglutide-based) medication programs with teleconsultations, at-home lab testing, and lifestyle coaching. The service delivers end-to-end obesity care via a mobile app and website, targeting individual adults seeking clinically-supervised weight management. Following its June 2026 acquisition by London-headquartered Voy, the offering now operates as Voy India.

Product overview

EarlyFit operates as a comprehensive digital weight loss platform offering a doctor-led GLP-1 obesity care program. The platform combines an online weight loss platform with mobile app functionality, providing medical consultations with endocrinologists, at-home GLP-1 medication delivery via cold chain, lifestyle coaching, smart body tracking, and at-home lab testing. Following its acquisition by UK-based Voy, the program now offers affordable generic semaglutide medications with a 10% body weight loss money-back guarantee.

Differentiator

Problem solved

Functional benefit

Products and services

• GLP-1 Weight Loss Program A structured, doctor-supervised treatment program using GLP-1 receptor agonist medication (semaglutide) for adults with overweight or obesity, including an initial consultation, prescription, follow-ups, and lifestyle coaching. Target users are individual consumers in India seeking medical weight loss.
• EarlyFit Mobile App A consumer mobile app that allows enrolled users to register, complete telehealth consultations with clinicians, track weight-loss progress, access coaching, and manage their treatment plan. Targeted at individual program participants in India.
• At-Home Lab Testing A home-based diagnostic testing service that collects blood and metabolic markers from enrolled users to support safe prescribing and progress monitoring of the weight loss program. Target users are individual program participants.
• Lifestyle Coaching Program A digital lifestyle coaching program providing nutritional guidance, activity planning, and habit-change support to complement medical treatment. Targeted at individual adults enrolled in the weight loss program.
• Generic Semaglutide Medication Generic semaglutide medication dispensed under clinician prescription to enrolled users as part of the weight loss program. Targeted at individual patients medically cleared for GLP-1 therapy.

Quantifiable outcome

• 53% more weight loss compared to medication-only providers
• +2 more outcomes

Named customers4 records

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Seven partnerships are on record, tiered core and flagship.

• VoycoreStrategic or Co-development Partner · 8 June 2026Voy, a London-headquartered digital healthcare company and market leader in GLP-1 obesity care, acquired 100% of EarlyFit to enter the Indian market. The acquisition brings Voy's global clinical expertise, technology, and integrated care model to India's 150 million obese population.
• Imperial College LondoncoreStrategic or Co-development PartnerResearch partnership for clinical studies on GLP-1 weight loss outcomes. Conducted study on 57,975 Voy participants showing 53% more weight loss vs medication-only providers.
• University of OxfordflagshipStrategic or Co-development PartnerAcademic partnership for research and clinical validation of GLP-1 obesity care programs.
• University of BirminghamflagshipStrategic or Co-development PartnerAcademic partnership for research collaboration in obesity care and digital health.
• Federal University of Minas GeraisflagshipStrategic or Co-development PartnerInternational academic partnership in Brazil for obesity research and clinical validation.
• Ulster UniversityflagshipStrategic or Co-development PartnerAcademic partnership for research collaboration in digital health and weight management.
• University of HertfordshireflagshipStrategic or Co-development PartnerAcademic partnership for research and clinical studies in obesity care.

Scale indicators7 records

Recent moves5 records

Expansion highlights5 records

Broad incumbents

• Tata 1mg: India's leading digital pharmacy and telehealth platform with diagnostic and consultation services. Broadly comparable as a scaled Indian digital health ecosystem that could enter the weight loss category.
• Practo: India's largest doctor appointment and telehealth platform serving 100M+ consumers. Comparable as a scaled Indian telehealth infrastructure that overlaps with the medical consultation and prescription layer of EarlyFit/Voy India's offering.
• Cult.fit (Cure.fit): India's largest fitness and wellness platform offering gym memberships, nutrition, and mental health services. Expanding into clinical health, broadly comparable as a vertically-integrated consumer health platform targeting urban Indians.
• Hims & Hers Health: US telehealth leader offering branded GLP-1 weight loss programs alongside broader wellness categories. Comparable as a scaled, vertically-integrated telehealth consumer health platform.

Direct peers

• HealthifyMe: India's leading digital health and weight loss platform offering AI-powered nutrition tracking, coaching, and now GLP-1 programs. Directly comparable as a doctor-supervised weight loss ecosystem serving the same Indian consumer base.
• Calibrate: US digital weight loss clinic combining GLP-1 medication with coaching and metabolic reset programs. Closely comparable in clinical positioning, subscription pricing, and outcome-based guarantees.
• Voy: London-based parent company of EarlyFit operating the same GLP-1 weight loss program across UK, Germany, Brazil, and now India. Same product, brand, and clinical model — effectively the global version of the EarlyFit platform.
• Found: US-based digital weight loss clinic offering medication (including GLP-1s) with clinical oversight and coaching. Closely comparable business model with subscription-based, doctor-supervised GLP-1 delivery.
• Noom: Global digital weight loss platform combining psychology-based coaching with calorie tracking and now GLP-1 support. Direct competitor in the behavioral coaching + medication weight loss category with comparable subscription model.
• Ro: US telehealth platform offering direct-to-consumer weight loss programs with GLP-1 prescriptions, lab testing, and ongoing care. Direct comparable in the integrated telehealth + medication + coaching category.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about EarlyFit